Use of phytocannabinoids in the treatment of ovarian carcinoma
US10098867B2 · kind B2 · utility
32Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 19, 2014 |
| Grant date | Oct 16, 2018 |
| Priority date | — |
| Expiry date | Jun 19, 2034 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of phytocannabinoids in the treatment of ovarian cancer. Preferably the phytocannabinoid is selected from the group consisting of: cannabidiol (CBD); cannabidiol acid (CBDA); cannabigerol (CBG); cannabigerolic acid (CBGA); cannabigerol propyl variant (CBGV); and tetrahydrocannabivarin (THCV). In a further embodiment the one or more phytocannabinoids are used in combination with each other. Preferably the combination of cannabinoids consists of CBD and CBG.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.